Will Boehringer Ingelheim win the race for anticoagulants?


Boehringer Ingelheim has released the last figures of its idarucizumab Phase III. The breakthrough anti-anticoagulant is being studied as an antidote to Boehringer’s blockbuster Pradaxa.

Pradaxa was the first widely approved drug in a new generation of direct oral anticoagulants, a blockbuster developed by Boehringer Ingelheim. However, there is no specific antidote available yet to manage life-threatening bleeding or when emergency surgery is necessary. To this aim, the Big Pharma is rushing to get the approval of idarucizumab, the direct antidote of its anti-coagulant.

First patient study data show that the anti-anticoagulant immediately reverses dabigatran, the active ingredient in Pradaxa, within minutes in patients requiring urgent procedures or with serious bleeding complications. The optimistic outcomes from the trial include data from 90 patients in emergency settings who were taking dabigatran and required reversal.

The competition to get the largest slice of the anticoagulant market is on.  Boehringer Ingelheim was definitely leading, with the wide approval of Pradaxa, but Pfizer-BMS and Bayer-Janssen also played their cards well. Both partnerships inserted themselves on the market thanks to the approval of Eliquis and Xarelto, respectively. However, to achieve first place, it is necessary to have the winning anticoagulant-antidote combo. Only Boehringer seems to be ahead again with idarucizumab being granted a Priority Review designation by the FDA.

Explore other topics: Germany

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More